According to the website Seeking Alpha, Brean Capital maintained its “buy” rating and raised the price target on Celldex Therapeutics Inc. to $35 from $25 per share, based on encouraging data about the experimental drug CDX-1127 to treat lymphoma. “Given the clean safety of CDX-1127, we believe combining CDX-1127 with other agents would be the path forward with CDX-1127 . . . and believe that auto immunelike toxicities that may emerge when combining CDX-1127 with another immune-stimulating agent can be managed,” analyst Jonathan Aschoff wrote.